UNSPSC 51112804: Raloxifene

This classification denotes a selective estrogen receptor modulator with the molecular formula C28H27NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YX9162EO3I, chemically known as methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)- but more generally known as raloxifene, which bears US NIH Compound Identifier 5035. European Medicines Agency schedules Raloxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10243MIG.

UNSPSC 51112804 Raloxifene is a Commodity code identifying a specific pharmaceutical product — in this case the osteoporosis medication raloxifene — that state and local health and human services agencies procure through pharmacy benefit programs and direct pharmaceutical supply channels. State procurement of raloxifene occurs primarily through health and human services departments managing pharmacy benefits for state employees, Medicaid populations, and other covered groups, though the code itself represents only one drug within a much broader pharmaceutical purchasing ecosystem. The Texas Health and Human Services Commission's recent activity under this code reflects the state's exploration of direct-to-manufacturer prescription programs as an alternative to traditional pharmacy benefit manager (PBM), group purchasing organization (GPO), and wholesaler arrangements — a shift in procurement strategy aimed at improving cost management and fulfillment efficiency across its pharmacy benefit portfolio.

The Texas Health and Human Services Commission issued Request for Information (RFI) No. HHS0017013 on April 3, 2026, seeking vendor capabilities and market intelligence regarding the implementation of a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program. The RFI solicits detailed vendor responses about capacity to enter direct contracts with self-insured employer and state agency health plans, experience with negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. As an exploratory procurement mechanism rather than a formal competitive solicitation, the RFI carries no award value, budget range, set-aside designations, or binding timelines; the state is conducting foundational research on available solutions and vendor capabilities to inform the development of detailed procurement specifications and pricing models for subsequent formal solicitations. The narrow scope of recent activity under this code and the preliminary nature of the Texas RFI suggest that raloxifene procurement remains concentrated within state health systems and does not currently appear to be a high-volume or actively contested commodity at the state and local level.